Skip to main content
Move the World.
FDA Approves First Mute Button for Genetic Diseases
Credit: Jeremy Keith

The FDA has just approved a breakthrough genetic treatment, a first of its kind therapy that silences a gene that causes amyloidosis and nerve damage. The treatment relies on RNAi, or "interfering" RNA, to block certain strands of DNA from being translated into proteins. Unlike traditional gene therapy, the technique doesn't remove or alter the underlying mutation, but it effectively "mutes" it so it can't do any damage.

Developed by Alnylam Pharmaceuticals, this is the first time that the technique has been approved to treat disease in humans, but scientists have used it for years to "knock down" genes in mice in order to model various diseases. The potential upside for therapies with RNAi is huge, which is why its discoverers won the Nobel Prize for Medicine in 2006. This is likely to be the first of many advanced treatments to deploy the technique. It also has widespread potential applications in agriculture, from suppressing natural toxins and allergens in crops to targeting pests and weeds.

How to Build Stuff (Or Not)

To wildly oversimplify things, your body is made of cells, and cells are made of proteins. To make proteins, cells use a molecule called RNA to carry instructions from your DNA to protein factories called ribosomes. RNA translates DNA from abstract code into specific instructions for assembling proteins.

Many types of genetic disease (whether inherited or developed later in life) are caused by cells making the wrong kind of protein—maybe it's misshapen, or toxic, or in the wrong organ, or there's simply too much of it. Traditional pharmaceuticals use chemical compounds to block the protein from doing its job, break it down, or suppress it from being made. But hitting the right target in complex chemical reactions is extremely challenging, and it can take literally decades of trial and error to find the right chemical.

Gene therapies try to go right for the source, by deleting or replacing the mutated DNA that has the bad protein instructions. But your cells really don't like anything messing with your DNA (for very good reason), so it's turned out to be difficult to edit enough cells (potentially billions of them) to make a dent in many diseases.

A Third Way

When pharmaceuticals and biotech fail, there's another approach, right in the middle: cut off RNA messengers before they can turn DNA into proteins. Fortunately, your body already has a process for doing this, called RNA interference (RNAi). Why would cells want to interfere with their own RNA? Often, it's just another way to control the rate of protein production, but it can also be a defense mechanism against viruses that try to sneak their RNA into the cell to hijack its protein machinery.

RNAi is a highly complex process, but fundamentally, it's a way to shred RNA before it can be translated into protein. Researchers have used the technique successfully to silence gene expression in mice to simulate diseases and then test treatments, and there's a number of applications in the works for modifying crops to remove natural allergens or toxins. In 2006, the discoverers of RNAi won the Nobel Prize in Medicine, and the 12 years since have been a race to develop and commercialize a new class of drugs based on their breakthrough.

The Drug

Alnylam won that race this month, and their therapy will be the first to use RNAi to treat disease in humans. The FDA approved only a very narrow use of the drug, treating neuropathy or nerve pain caused by a rare hereditary form of amyloidosis. But some experts believe that it could eventually be approved for treating heart damage, another serious effect of amyloidosis, and even the non-hereditary forms of the disease, which are still ultimately caused by the overproduction of amyloid protein.

The company has three other RNAi drugs in the pipeline, likely headed for approval soon, intended to treat causes of high cholesterol, porphyria, and hemophilia. FDA Commissioner Scott Gottlieb made optimistic comments about the future of RNAi therapies in his press release announcing the drug's approval: "This approval is part of a broader wave of advances that allow us to treat disease by actually targeting the root cause, enabling us to arrest or reverse a condition, rather than only being able to slow its progression or treat its symptoms."

"New technologies like RNA inhibitors,that alter the genetic drivers of adisease, have the potential to transformmedicine."

Scott GottliebFDA Commissioner

This drug, the crest of that wave of innovation, will come at a steep price—nearly $350,000, even after discounts. At that price, Alnylam hopes to rapidly recoup its estimated $2.5 billion investment in research and development, but insurance companies and governments will likely balk at the cost. It remains to be seen if these treatments can become either widespread or cost effective with mid-six-figure sticker prices.

Up Next

Healthcare
Personalized Blood Test for Cancer Hunts Down Tumor DNA
Blood Test for Cancer
Healthcare
Personalized Blood Test for Cancer Hunts Down Tumor DNA
A newly unveiled personalized blood test for cancer monitoring has a sensitivity 10 times that of existing liquid biopsy methods.

A newly unveiled personalized blood test for cancer monitoring has a sensitivity 10 times that of existing liquid biopsy methods.

Making Tumors Glow to Improve Cancer Surgery
Making Tumors Glow to Improve Cancer Surgery
Watch Now
Making Tumors Glow to Improve Cancer Surgery
This surgeon is improving surgery by lighting up cancer cells.
Watch Now

This surgeon, Dr. Sunil Singhal, is making tumors glow to help doctors ensure they have removed all of the cancer cells at the surgery site. Completely removing cancer tumors can be difficult, and if a small amount remains, the cancer can recur. Sunil, the director of the Thoracic Surgery Research Laboratory at the University of Pennsylvania, came up with the idea of using glowing tumors to advance cancer surgery after an...

Dispatches
We're Mapping 100 Trillion Human Cells (and All of Their Genes)
We're Mapping 100 Trillion Human Cells (and All of Their Genes)
Dispatches
We're Mapping 100 Trillion Human Cells (and All of Their Genes)
The "Human BioMolecular Atlas" will map the active genes in over 200 types of cells and 80 different organ systems.
By Mark Atkinson

The "Human BioMolecular Atlas" will map the active genes in over 200 types of cells and 80 different organ systems.

Dispatches
Genetic Tests Miss “Invisible” Mutations That Cause Disease and Neurological...
Genetic Tests Miss “Invisible” Mutations That Cause Disease and Neurological Disorders
Dispatches
Genetic Tests Miss “Invisible” Mutations That Cause Disease and Neurological...
There's more to your DNA than just letters, and mutations can lurk in that genetic "dark matter."

There's more to your DNA than just letters, and mutations can lurk in that genetic "dark matter."

Dispatches
23andMe Can (Finally) Tell You about Your Genetic Cancer Risk
23andMe Can (Finally) Tell You about Your Genetic Cancer Risk
Dispatches
23andMe Can (Finally) Tell You about Your Genetic Cancer Risk
23andMe has won the right to tell you what your genes say about you. It's a landmark legal achievement that could...

23andMe has won the right to tell you what your genes say about you. It's a landmark legal achievement that could help usher in a new age of personalized medicine.

Coded
From Multi-Millionaire Bitcoin Entrepreneur to Inmate and Back Again
From Multi-Millionaire Bitcoin Entrepreneur to Inmate and Back Again
Coded
From Multi-Millionaire Bitcoin Entrepreneur to Inmate and Back Again
The story of how Charlie Shrem built his business as a Bitcoin pioneer, lost it all, and is now clawing his way back.
By Michael O'Shea

The story of how Charlie Shrem built his business as a Bitcoin pioneer, lost it all, and is now clawing his way back.

Superhuman
Meet the Paralyzed Man Who Can Walk Again
Meet the Paralyzed Man Who Can Walk Again
Superhuman
Meet the Paralyzed Man Who Can Walk Again
Robert is paralyzed from the chest down. But now a robotic exoskeleton is giving him what he calls "a second chance...
By Mike Riggs

Robert is paralyzed from the chest down. But now a robotic exoskeleton is giving him what he calls "a second chance at life."